|Bid||0.00 x 1200|
|Ask||135.00 x 800|
|Day's range||129.53 - 131.94|
|52-week range||113.52 - 169.82|
|Beta (3Y monthly)||0.99|
|PE ratio (TTM)||11.83|
|Earnings date||4 Nov. 2019 - 8 Nov. 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||170.38|
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
How far off is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) from its intrinsic value? Using the most recent financial data...
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
In 2009 Bruce Cozadd was appointed CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ). First, this article will compare CEO...